Murray Yule

Murray is the Chief Medical Officer of iOmx. He is a United Kingdom trained and board-certified medical oncologist who has worked in the European pharma industry for almost 20 years, planning and delivering clinical trials across the EU, US and Asia. Prior to joining the industry he worked at the MD Anderson Cancer Center in Houston and the University of Cambridge in the United Kingdom. Whilst at Eisai, Murray played a pivotal role in the successful licensing of Halven for the treatment of advanced breast cancer and liposarcoma. Immediately prior to joinng iOmx, Murray worked on the FDA approval of Tafasitamab for the treatment of Non Hodgkins Lymphoma at MorphoSys AG. Murray has been a member of the Scientifc Boards of Adcendo and Almac Discovery and has deep experience across a wide range of therapeutic approaches in the treatment of cancer from small molecules to cellular therapy. He has extensive experience in partnering within the pharma industry and successfully listed Xynomic on the Nasdaq stock exchange.